Literature DB >> 18640019

ANCA-associated lung fibrosis: analysis of 17 patients.

Guillaume Foulon1, Philippe Delaval, Dominique Valeyre, Benoît Wallaert, Marie-Pierre Debray, Michel Brauner, Pascale Nicaise, Jacques Cadranel, Vincent Cottin, Abdellatif Tazi, Michel Aubier, Bruno Crestani.   

Abstract

In this retrospective study, we analyzed 17 patients presenting with pulmonary fibrosis and a positive ANCA testing. This group was compared with a control group of 12 patients with IPF and negative ANCA testing. Patients were 15 males and 2 females, with a mean age of 66 years. Eight patients were past smokers, 3 current smokers and 6 non-smokers. Lung function tests at diagnosis were as follows (% predicted): total lung capacity 73%+/-18, vital capacity 82%+/-23, forced expiratory volume in 1 s (FEV(1)) 88%+/-24, carbon monoxide diffusion capacity of the lung 49%+/-2 (% predicted). Bronchoalveolar lavage results showed an increased cellularity with increased neutrophils counts. High resolution computed tomography of the chest showed prominent fibrosis with some degree of ground-glass attenuation in all patients. These characteristics were similar to the control group. Microscopic polyangiitis (MPA) was a major complicating event in ANCA-positive patients, occurring in 7 patients (anti-myeloperoxidase specificity in 5 patients). Pulmonary fibrosis predated occurrence of MPA in 6 patients and was diagnosed concomitantly with MPA in 1 patient. During the follow-up, 10/17 patients died. The death was directly related to vasculitis in 3 patients. We conclude that patients with pulmonary fibrosis should be evaluated for the presence of ANCA. Patients with positive ANCA testing, particularly if anti-myeloperoxidase, should be carefully monitored to detect the occurrence of microscopic polyangiitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640019     DOI: 10.1016/j.rmed.2008.04.023

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  26 in total

1.  Radiologic and pathologic characteristics of myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease: a retrospective analysis.

Authors:  Misbah Baqir; Eunhee E Yi; Thomas V Colby; Christian W Cox; Jay H Ryu; Ulrich Specks
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 2.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

3.  Microscopic polyangiitis associated with pulmonary fibrosis.

Authors:  Marcelo Fernandez Casares; Alejandra Gonzalez; Mariano Fielli; Flavia Caputo; Yanina Bottinelli; Marcelo Zamboni
Journal:  Clin Rheumatol       Date:  2014-05-27       Impact factor: 2.980

4.  Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Gabrielle Y Liu; Iazsmin Bauer Ventura; Natalia Achtar-Zadeh; Brett M Elicker; Kirk D Jones; Paul J Wolters; Harold R Collard; Ayodeji Adegunsoye; Mary E Strek; Brett Ley
Journal:  Chest       Date:  2019-06-07       Impact factor: 9.410

Review 5.  Microscopic polyangiitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Rheum Dis Clin North Am       Date:  2010-06-11       Impact factor: 2.670

6.  Pyrexia of unknown origin and pulmonary fibrosis as a presentation of MPO-ANCA associated vasculitis.

Authors:  O Shields; A Shah; B Mann
Journal:  BMJ Case Rep       Date:  2011-04-15

7.  Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias.

Authors:  Hironao Hozumi; Noriyuki Enomoto; Yoshiyuki Oyama; Masato Kono; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Takafumi Suda
Journal:  Lung       Date:  2016-02-12       Impact factor: 2.584

8.  Pulmonary fibrosis-an uncommon manifestation of anti-myeloperoxidase-positive systemic vasculitis?

Authors:  Amir Bhanji; Mahzuz Karim
Journal:  NDT Plus       Date:  2010-04-14

Review 9.  Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist.

Authors:  Sakae Homma; Aika Suzuki; Keita Sato
Journal:  Clin Exp Nephrol       Date:  2012-11-28       Impact factor: 2.801

Review 10.  Limited pulmonary MPA, a new MPA entity? A rheumatologist's perspective.

Authors:  Luis F Flores-Suárez
Journal:  Clin Exp Nephrol       Date:  2012-11-28       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.